[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349859-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-349859-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","gastrointestinal-adverse-events-following-brentuximab-vedotin-and-polatuzumab-vedotin-therapy","Gastrointestinal adverse events following brentuximab vedotin and polatuzumab vedotin therapy","","Brentuximab vedotin (BV) and polatuzumab vedotin (PV) are targeted antibody–drug conjugates used for hematologic cancers, and both can trigger gastrointestinal adverse events (GI AEs). A retrospective cohort of 879 adult patients treated at a tertiary cancer center from March 1, 2016 to March 31, 2023 identified 64 eligible cases, excluding alternate diagnoses. Median onset was 37 days, with diarrhea and abdominal pain as common symptoms, supportive care as predominant management, symptom resolution in most patients, and recurrence and therapy discontinuation observed in subsets.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/gastrointestinal-adverse-events-following-brentuximab-vedotin-and-polatuzumab-vedotin-therapy/349859/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/gastrointestinal-adverse-events-following-brentuximab-vedotin-and-polatuzumab-vedotin-therapy/349859.png","ImageObject",300,407,{"name":42,"@type":43},"Asher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-09-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":26},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"What is the study’s primary objective regarding GI adverse events after BV or PV therapy?","Question",{"text":62,"@type":63},"To assess clinical characteristics, disease course, treatment approaches, and outcomes in patients who developed gastrointestinal adverse events following BV or PV.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"How many patients were ultimately included, and what was the median time to GI AE onset?",{"text":67,"@type":63},"Sixty-four patients were included, with a median duration of 37 days from therapy initiation to GI AE onset.",{"name":69,"@type":60,"acceptedAnswer":70},"What treatments were most commonly used, and how often did symptoms resolve?",{"text":71,"@type":63},"Most patients received supportive care alone; a smaller number received corticosteroids. Symptom resolution occurred in most patients (93%) after treatment.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},349859,1790207298,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,109,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":107,"slug":108},7,40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},8,"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":106,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":26,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Gastrointestinal adverse events following brentuximab vedotin and polatuzumab vedotin therapy  \nAndrew G. Kuang, Malek Shatila, Jay S. Shah, Nitish Mittal, Sidra Naz, Ugochi Ebinama, Swaminathan P. Iyer, Paolo Strati, Mehnaz A. Shafi, Anusha S. Thomas, Hao Chi Zhang andYinghong Wang  \nAbstract  \nBackground: Brentuximab vedotin (BV) and polatuzumab vedotin (PV), CD30-specific and CD79b-specific monoclonal antibody conjugates, respectively, are used in the treatment of hematologic cancers. Both have been observed to cause gastrointestinal adverse events (GIAEs) .  \nObjectives: We aimed to assess the clinical characteristics, disease course, treatment, and outcomes of patients who developed GI AEs following treatment with BV or PV.  \nDesign: We retrospectively identified 879 adult cancer patients who received BV or PV therapy between March 1, 2016, and March 31, 2023, at our tertiary cancer center. Patients with alternate diagnoses were excluded.  \nMethods: Clinical characteristics, management, and outcomes of GI AEs were retrospectively evaluated and statistically analyzed.  \nResults: Sixty-four patients were included, and the median duration from therapy initiation to GI AE onset was 37 days. GI AEs occurred in the lower gastrointestinal tract (78%), upper gastrointestinal tract (45%), hepatobiliary system (11%), and pancreatic system (4 .3%) . Common symptoms were diarrhea (77%), nausea (61%), and abdominal pain (52%) . Some patients had Common Terminology Criteria for Adverse Events grade ⩾3 toxicity (19% with diarrhea and 2. 7% with colitis symptoms) . Most patients (81%) received supportive care alone, and three received corticosteroids. Most patients (93%) achieved symptom resolution following treatment. Symptoms recurred in 37% of patients, and 41% of patients stopped BV/ PV therapy due to GI AE.  \nConclusion: GI AEs following the use of targeted antibody–drug conjugates can involve various gastrointestinal systems. In our patient cohort who received BV or PV, GI AEs were typically low grade and managed with supportive care or corticosteroids. Nonetheless, some patients experienced high-grade AEs or symptom recurrence and stopped BV/PV therapy. Future studies may provide clarification and guide clinical practice.  \nKeywords: brentuximab vedotin, gastrointestinal adverse event, monoclonal antibody–drug conjugate, polatuzumab vedotin  \nReceived: 17 May 2025; revised manuscript accepted: 6 January 2026.  \nIntroduction  \nGastrointestinal adverse events (GI AEs) can occur with many types of cancer therapies, including those with immune checkpoint inhibitors (ICIs), whose adverse effects have been  \nwell studied. 1,2 Brentuximab vedotin (BV) and polatuzumab vedotin (PV), CD30-specific and CD79b-specific monoclonal antibody–drug conjugates, respectively, have been approved for the treatment of select hematologic malignancies,  \nTherAdv Med Oncol 2026, Vol. 18: 1–12  \nDOI: 10. 1177/ 17588359261417635 © The Author(s), 2026.  \nArticle reuse guidelines: [sagepub.com/journals](sagepub.com/journals)permissions  \nCorrespondence to:  \nYinghong Wang  \nDivision of Internal Medicine, Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1466, Houston, TX 77030, USA  \nywang59@mdanderson. org  \nAndrew G. Kuang  \nDivision of Gastroenterology and Hepatology, Department of Medicine, University of Pennsylvania Health System, Philadelphia, PA, USA  \nMalek Shatila Sidra Naz  \nMehnaz A. Shafi Anusha S. Thomas Hao Chi Zhang  \nDivision of Internal Medicine, Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA  \nJay S. Shah  \nDepartment of Medicine, Baylor College of Medicine, Houston, TX, USA  \nNitish Mittal Ugochi Ebinama  \nDepartment of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA  \nSwaminathan P. Iyer Paolo Strati  \nDivision of Cancer Medicine,","cbCaicv88WBOpzT5","https://ap.wps.com/l/cbCaicv88WBOpzT5","pdf",694867,12,"English","# Abstract\n# Introduction\n# Methods","[{\"question\":\"What is the study’s primary objective regarding GI adverse events after BV or PV therapy?\",\"answer\":\"To assess clinical characteristics, disease course, treatment approaches, and outcomes in patients who developed gastrointestinal adverse events following BV or PV.\"},{\"question\":\"How many patients were ultimately included, and what was the median time to GI AE onset?\",\"answer\":\"Sixty-four patients were included, with a median duration of 37 days from therapy initiation to GI AE onset.\"},{\"question\":\"What treatments were most commonly used, and how often did symptoms resolve?\",\"answer\":\"Most patients received supportive care alone; a smaller number received corticosteroids. Symptom resolution occurred in most patients (93%) after treatment.\"}]","Gastrointestinal adverse events following brentuximab vedotin and polatuzumab vedotin therapy | PDF",1790086005]